Clinical Trial: Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title:
Brief Summary: This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.
Detailed Summary:
Sponsor: Allergan
Current Primary Outcome:
- Number of Participants With Adverse Events [ Time Frame: Up to 12 Months ]
- Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey [ Time Frame: Baseline, Month 1 ]
- Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey [ Time Frame: Baseline, Month 4 ]
- Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey [ Time Frame: Baseline, Month 12 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Allergan
Dates:
Date Received: July 21, 2015
Date Started: December 2014
Date Completion: June 2018
Last Updated: January 19, 2017
Last Verified: January 2017
